InvestorsHub Logo
Followers 24
Posts 1171
Boards Moderated 0
Alias Born 01/27/2021

Re: marjac post# 405958

Friday, 03/17/2023 2:31:01 PM

Friday, March 17, 2023 2:31:01 PM

Post# of 426045
I'm not surprised that your legal analysis sounds spot on, since you are essentially this message board's counsel in residence. So thanks for that.

I do hope Amarin vigorously pursues the appeal of Hikma being knocked out of the infringement lawsuit by the district judge in Delaware. I think that's the company's best avenue to recoup some of the damage done by Judge Du. It also helps that the magistrate judge ruled the other way in what seemed like a sound legal analysis. Just as it helps to have multiple judges in disagreement in any appeal, it should carry some weight that the magistrate judge saw it differently. And for good reason, as we all know. And even the district judge during oral arguments acknowledged that somebody had to be to blame for all the prescriptions being written now that seem to violate the heart indication Amarin earned from the FDA in early 2020.

Besides an opportunity to slow or stop the rampant violation of its patents, Amarin has a shot at a little revenge against Hikma if it can have the lawsuit restored.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News